Demystifying Investing in the HealthTech Sector – New South Wales

MTPConnect is Australia’s Life Sciences Innovation Accelerator – an independent, not-for-profit organisation formed by the Australian Government to champion the continuing growth of Australia's vibrant medical products sector. Forging stronger connections between research and industry to help maximise opportunities for Australians to not only make scientific and technological breakthroughs, but to see them developed through the proof-of-concept stage and successfully translated and commercialised. In this way, MTPConnect is building a more resilient and competitive medical products sector.

MTPConnect

Demystifying Investing in the HealthTech Sector  -  Join us for this unique MTPConnect Investor event in Sydney!

Hyatt Regency Sydney

<h3>Investor-only Workshop 2022</h3><p>It is our pleasure to invite you to <a href="https://www.mtpconnect.org.au/programs/REDI" target="_blank" data-msys-clicktrack="0" rel="nofollow noopener noreferrer">MTPConnect REDI</a> <strong>Demystifying Investing in the HealthTech Sector</strong> workshop and networking event for investors.</p><p>Join us in Sydney on Monday 25 July for a 3-hour in-person workshop followed by networking. Meet and connect with other healthtech investment specialists and investors.</p><p>Registration opens at 1:30pm for a 2:00pm start.</p><h3></h3><h3>Why attend?</h3><ul><li>Hear from investors and experts in the Medtech, Biotech and Pharmaceutical (MTP) sector</li><li>Improve your knowledge about the benefits and risks of investing in MTP companies</li><li>Learn to assess investment opportunities</li><li>Meet with fellow investors and grow your network</li></ul><p>The event is open to all investors seeking to increase their knowledge of the MTP sector and is <strong>free of charge</strong>. </p><p>Seats are strictly limited and for investors-only.</p><p></p><h3>Agenda:</h3><ul><li>1:30pm - Registration</li><li>2:00-3:35pm - Workshop: Rob McInnes and Richard Dale, Sydney Angels</li><li>3:35-3:55pm - Venture Capital Speaker: What to look for when investing</li><li>3:55-4:10pm - Break</li><li>4:10-5:00pm - Panel Discussion including Katherine Jackman, Brandon Capital</li><li>5:00-6:00pm - Networking and canapés</li></ul><h3></h3><h3>About the speakers:</h3><p><strong>Rob McInnes</strong> is a Committee member of Sydney Angels, and the Principal of his solo law practice Rob McInnes IP Advisory, which he founded after working for 30 years in large law and patent attorney firms.  He specialises in IP transactions and advises clients on the management and commercialisation of IP rights and due diligence on the IP positions of technology start-ups.  </p><p>Rob holds a degree in chemistry and has been an in-house Manager of IP and Technology Transfer with a multinational company.  He is an active angel investor with more than 20 portfolio companies, a Limited Partner in several VC funds, and a volunteer mentor at a number of start-up programs.</p><p>For the past decade Rob has been ranked as Australia’s most highly recommended patent and technology licensing lawyer, but these days he is trying to do less law and more investing.  </p><p><strong>Richard Dale</strong> is based in Sydney and has more than 30 years’ experience in top-tier management consulting, new venture development, venture capital, and R&D engineering. Since 2005 he has been a self-employed independent licensed adviser (Dale Advisers Pty Ltd AFSL 298916), providing strategy and funding solutions to Australian technology companies, from spinouts and startups, up to medium-size private companies with global opportunities.</p><p>As Partner NSW Universities for Campus Plus Pty Ltd, Richard also helps universities with their commercialisation process and projects, including spin-outs, and researcher and industry engagement.</p><p>Richard is heavily involved in the start-up ecosystem in a pro-bono capacity as co-founder and committee member of Sydney Angels, an angel group established in 2008. Its 120 members invest through a team-based process in innovative early-stage companies with high growth potential (83 to date, $33M directly invested, attracting a further $460M). Early-stage investments in medical technology startups include Atomo Diagnostics and Clarity Pharmaceuticals, both now ASX listed companies.</p><p>Richard holds a Bachelor of Engineering with 1st Class Honours from the University of Western Australia, and an MBA from London Business School.</p><p><strong>Katherine Jackman</strong> is a Senior Associate at Brandon Capital since 2016. Prior to joining, Kath was based in academia working in the field of experimental stroke. She spent 5 years at Weill Cornell Medicine-New York Presbyterian Hospital as a NHMRC CJ Martin and American Australian Association Sir Keith Murdoch fellow, before returning to the Florey Institute in Melbourne.</p><p>During her time in academia she secured competitive research funding from both the NHMRC and Brain Foundation of Australia. Kath is a board observer of Allay Therapeutics. Kath has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Pharmacology from the University of Melbourne and an MBA (Deans’ Honours list) from the Melbourne Business School.</p>

<p>For further information please get in touch with Jarrod Belcher, Director REDI Initiative, on +61 402 456 301 or at REDI@mtpconnect.org.au.  </p><p><strong>DISCLAIMER:</strong> The material in this workshop is intended to provide a general summary only and should not be relied on as a substitute for legal or other professional advice. You should obtain your own legal or other professional advice.</p>

Our {communityGuidelinesLink} describe the sort of content we prohibit on Eventbrite. If you suspect an event may be in violation, you can report it to us so we can investigate.

To report other categories of prohibited or illegal content, submit {link}